FDA.reportPublic FDA data

STREPTOCOCCUS PNEUMONIAE TYPE 19F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN Pharmacologic Class Indexing

Class set ID
61ad4e82-13f6-458b-b07f-4e19d7937756
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use VAXNEUVANCE safely and effectively. See full prescribing information for VAXNEUVANCE. VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) Suspension for Intramuscular Injection Initial U.S. Approval: 2021Merck Sharp & Dohme LLC2026020914
These highlights do not include all the information needed to use PREVNAR 20 safely and effectively. See full prescribing information for PREVNAR 20. PREVNAR 20 ® (Pneumococcal 20-valent Conjugate Vaccine), suspension for intramuscular injection Initial U.S. Approval: 2021A-S Medication Solutions2025081313
These highlights do not include all the information needed to use PREVNAR 20 safely and effectively. See full prescribing information for PREVNAR 20. PREVNAR 20 ® (Pneumococcal 20-valent Conjugate Vaccine), suspension for intramuscular injection Initial U.S. Approval: 2021Wyeth Pharmaceutical Division of Wyeth Holdings LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC | Pfizer Manufacturing Belgium NV | Pfizer Inc2025071811
These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. See full prescribing information for PREVNAR 13. PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]) Suspension for intramuscular injection Initial U.S. Approval: 2010A-S Medication Solutions2024052426